Paper17538158
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?
Welch SA and 1 other. J Clin Oncol, 2007. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag? Papers, record 17538158. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538158
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Pancreatic Neoplasms | Major topic |
| Capecitabine | |
| Deoxycytidine | |
| ErbB Receptors | |
| Fluorouracil | |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Gemcitabine |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 17538165 | Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. | https://conductscience.org/library/papers/17538165 |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36618103 | Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. | Glob Chall | 2023 | https://conductscience.org/library/papers/36618103 | PubMed |
| 29998365 | Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. | Invest New Drugs | 2019 | https://conductscience.org/library/papers/29998365 | PubMed |
| 28353074 | Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. | Target Oncol | 2017 | https://conductscience.org/library/papers/28353074 | PubMed |
| 26317650 | An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. | Oncotarget | 2015 | https://conductscience.org/library/papers/26317650 | PubMed |
| 23846417 | Considerations for the prediction of survival time in pancreatic cancer based on registry data. | J Pharmacokinet Pharmacodyn | 2013 | https://conductscience.org/library/papers/23846417 | PubMed |
| 22233582 | Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. | Mol Ther | 2012 | https://conductscience.org/library/papers/22233582 | PubMed |
| 21740354 | Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. | Curr Pharm Biotechnol | 2012 | https://conductscience.org/library/papers/21740354 | PubMed |
| 20726858 | Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. | Cancer Sci | 2010 | https://conductscience.org/library/papers/20726858 | PubMed |
| 20101258 | Advanced pancreatic carcinoma: current treatment and future challenges. | Nat Rev Clin Oncol | 2010 | https://conductscience.org/library/papers/20101258 | PubMed |
| 19405981 | Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. | BMC Cancer | 2009 | https://conductscience.org/library/papers/19405981 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17538158
GET https://conductscience.org/api/papers/v1/17538158/authors